The PD-1/PD-L1 inhibitors, approved by the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA) for the treatment of advanced NSCLC (Xu et al., 2018) (Table 2) domestic preparations include Sintilimab (PD-1, February 2021), Camrelizumab (PD-1, December 2021), Tislelizumab (PD-1, June 2021; approved in China for the treatment of NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.